Special Issue "15 Years of Tissue Microarray Technology: The Changing Scenario of Tissue-Based Translational Research"
A special issue of Microarrays (ISSN 2076-3905).
Deadline for manuscript submissions: closed (31 March 2015)
Prof. Dr. Luigi Terracciano (Website)
Molecular Pathology Division, Institute of Pathology, University Hospital, Schönbeinstrasse 40, CH-4003 Basel, Switzerland
Phone: +41 61 2652849
Fax: + 4161 2653194
Interests: molecular pathology; translational research; cancer stem cells; hepatic carcinogenesis; drug-induced liver diseases
In the last two decades the progress in the knowledge of molecular genetics and the availability of high-throughput technologies has offered the opportunity to identify new diagnostic and prognostic markers and new therapeutic targets in human cancer. Among the several different high-throughput technologies made available, tissue microarray (TMA) technology has significantly accelerated in situ studies of tissue specimens, to explore associations between molecular changes and clinico pathological information and to ensure preservation of unique and precious research materials. TMAs have been used for various molecular analyses that can also be performed on regular tissue sections, including immunohistochemistry, fluorescence in situ hybridization (FISH) and mRNA in situ hybridization. Virtually all kinds of tissues or cells have been converted to a microarray format. Therefore, TMA applications cover all fields of microscopic analyses of tissues and cells. In the case of cancer research, TMA has significantly facilitated the ability of basic scientists to extend in vitro studies of genes, proteins and signalling pathways to the in vivo situation radically changing the landscape of tissue-based translational research.
In this issue we are inviting material about new developments and applications of tissue microarray based technology, mainly in field of translational cancer research including screening for diagnostic, prognostic as well as predictive biomarkers, discovery of molecular alterations in different stages of tumor progression, assessment of new drug targets and quality controls.
Prof. Dr. Luigi Terracciano
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microarrays is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 300 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- tissue microarray
- high throughput
- prognostic biomarkers
- predictive biomarkers
- fluorescence in situ hybridization
- drug discovery
- quality control
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: HOX-proteins as diagnostic, prognostic and predictive cancer biomakers by Tissue Microarray Technology
Authors: Luca Quagliata 1 and Clemente Cillo
Affiliations: 1 Institute of Pathology, Molecular Pathology Division, University Hospital of Basel, Basel, Switzerland; 2 Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy; E-Mails: Luca.Quagliata@usb.ch; email@example.com
Abstract: The recent mapping of the epigenome, the epigenetic modifications of the human genome, has highlighted that both, genome-epigenome, work together in normal cells and along disease such as cancer. The most important epigenetic modifications include acetilation, phosphorilation, ubiquitination and methylation of histone tail proteins on Lys, Ser and Arg residues as well as methylation of DNA on cytosine. The stability of the epigenetic marks lasts shortly on the genome but methylation, because the chemical stability of methyl groups hampers rimotion. Thus, methylation is a transmissible key epigenetic process. The fate of each cell of our body is due to the cell memory gene program including three families of genes, Polycomb (Pbx), Trithorax (Trx) and Hox. Pbx (H3K27me3) and Trx (H3K4me3) maintain DNA-chromatin interaction in a compact/open configuration respectively, Hox genes control the execution of cell-specific gene programs through the regulation of transcription, export and translation of mRNAs. This confers to the cell memory gene program and to the Hox gene network a central stage of the epigentic processes. Detection of specific HOX proteins altered in human cancers can thus be crucial as diagnostic, prognostic and predictive biomarkers in the biological and clinical management of cancer. The use of TMA technology will greatly improve the identification of the role played by homeoproteins in human cancers.
Keywords: HOX genes; HOX-proteins; Homeoproteins; TMA